Table 4.
Spearman's Rank Correlation Coefficients for Complement Activation Products and Cytokines in the Aqueous Humor of Patients with CNV and in Controls
| C3a | C4a | C5a | VEGF | MCP-1 | |
|---|---|---|---|---|---|
| Controls | |||||
| C3a | 1 | — | — | — | — |
| C4a | 0.767* | 1 | — | — | — |
| C5a | 0.619* | 0.625* | 1 | — | — |
| VEGF | 0.321 | 0.405* | 0.263 | 1 | — |
| MCP-1 | 0.511* | 0.578* | 0.351* | 0.589* | 1 |
| PNV | |||||
| C3a | 1 | — | — | — | — |
| C4a | 0.578* | 1 | — | — | — |
| C5a | 0.045 | 0.133 | 1 | — | — |
| VEGF | –0.049 | –0.029 | 0.164 | 1 | — |
| MCP-1 | 0.187 | 0.142 | –0.089 | 0.372 | 1 |
| PCV | |||||
| C3a | 1 | — | — | — | — |
| C4a | 0.402 | 1 | — | — | — |
| C5a | 0.235 | –0.142 | 1 | — | — |
| VEGF | 0.601* | 0.295 | 0.218 | 1 | — |
| MCP-1 | 0.608* | 0.452* | –0.101 | 0.767* | 1 |
| Drusen-associated nAMD | |||||
| C3a | 1 | — | — | — | — |
| C4a | 0.664* | 1 | — | — | — |
| C5a | 0.501* | –0.012 | 1 | — | — |
| VEGF | 0.331 | 0.325 | 0.281 | 1 | — |
| MCP-1 | 0.619* | 0.452* | 0.444* | 0.629* | 1 |
*
P < 0.05 was considered significant.